DISTINGUISHED FACULTY

Ubiquitin Drug Discovery and Diagnostics 2010

Date: August 23, 2010 — August 25, 2010
Location: Four Seasons Hotel, Philadelphia, PA

DISTINGUISHED FACULTY DETAILS

View the Organizing Committee and Distinguished Faculty

DISTINGUISHED FACULTY (Partial List)

Christopher P. Austin M.D., PhD.

Director of the NIH Chemical Genomics Center, Bethesda MD

Dr. Austin is trained in developmental genetics and medical neurology and built a group in the 1990's at Merck that used genetic and genomic approaches to identify and validate novel targets for neuropsychiatric diseases. Dr. Austin developed innovative microarray and molecular histology gene expression capacities to functionally characterize novel genes. Finally, Dr. Austin initiated a Merck-wide effort to incorporate pharmacogenomics into target validation and drug development throughout the company.

Joseph Bolen, PhD.

Chief Scientist Officer, Millennium: The Takeda Oncology Company

Dr. Bolen joined Millennium in 1999 as Vice President of Oncology and was promoted to Senior Vice President of Discovery Research in 2002. In this role, he headed all biological research in the areas of oncology, inflammation, metabolic disease and cardiovascular disease as well as all genomics, informatics and platform technologies. In 2003 Dr. Bolen was appointed Senior Vice President of Research and Drug Discovery, a role in which he headed all biological research and related functions as well as all drug discovery functions. Dr. Bolen was appointed Chief Scientific Officer in 2006.

Alfred Goldberg, PhD.

Professor of Cell Biology, Harvard Medical School, Cambridge MA

Dr Goldberg is one of the true pioneers of the ubiquitin field, having first described the tagging and degradation of proteins in the 1960s.

J. Wade Harper, PhD.

Professor of Pathology, Harvard Medical School, Cambridge MA

Mark W. Hochstrasser, PhD.

Professor of Molecular Biophysics and Biochemistry, Yale University, New Haven CT

Ubiquitin's cousins - SUMO, ISG15, and others, are becoming increasingly interesting as therapeutic targets, being linked to critical cellular control mechanisms and a number of diseases including cancer and diabetes.

Benedikt M. Kessler, PhD.

Ubiquitin Proteolysis Group Nuffield Department of Clinical Medicine, Oxford University UK

Dr. Benedikt Kessler is a University Research Lecturer, Group Head / PI, Supervisor, Fellow, Member of congregation and Grant Holding Senior Scientist.

Keith Wilkinson, PhD.

Professor of Biochemistry, Emory University School of Medicine

Several of the nearly 100 known Deubiquitylating enzymes (DUBs) have been linked with various diseases, including cancer, neurodegenerative disease, and bacterial infection. Inhibitors and activators of DUBs are being studied and evaluated as potential therapies for these diseases.

Paul Andrews, PhD.

Scientist at Amgen Inc., Cambridge, MA

Dr. Andrews is a Scientist in Amgen Inc. in the Lead Discovery Organization and he is specialising in the ubiquitin proteasome pathway.

Jonathan D. Wrigley, PhD.

AstraZeneca, Cheshire UK